Menu Search
Equities

Medpace Holdings Inc

MEDP:NSQ

Medpace Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)337.82
  • Today's Change0.07 / 0.02%
  • Shares traded306.77k
  • 1 Year change+21.95%
  • Beta1.3690
Data delayed at least 15 minutes, as of Nov 25 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Medpace Holdings Inc grew revenues 29.17% from 1.46bn to 1.89bn while net income improved 15.26% from 245.37m to 282.81m.
Gross margin29.69%
Net profit margin17.66%
Operating margin19.74%
Return on assets20.48%
Return on equity54.06%
Return on investment43.51%
More ▼

Cash flow in USDView more

In 2023, Medpace Holdings Inc increased its cash reserves by 768.38%, or 217.18m. The company earned 433.37m from its operations for a Cash Flow Margin of 22.98%. In addition the company used 34.63m on investing activities and also paid 182.64m in financing cash flows.
Cash flow per share12.32
Price/Cash flow per share26.62
Book value per share28.42
Tangible book value per share5.94
More ▼

Balance sheet in USDView more

Medpace Holdings Inc uses little or no debt in its capital structure.
Current ratio0.9916
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 21.88%. Additionally, five year annualized earnings per share growth ranks above the industry average relative to its peers.
EPS growth(5 years)35.10
EPS (TTM) vs
TTM 1 year ago		33.78
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.